How to buy Fulgent Genetics stock | 46.05

Fulgent Genetics, Inc is a diagnostics & research business based in the US. Fulgent Genetics shares (FLGT) are listed on the NASDAQ and all prices are listed in US Dollars. Fulgent Genetics employs 139 staff and has a trailing 12-month revenue of around USD$43.8 million.

How to buy shares in Fulgent Genetics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Fulgent Genetics. Find the stock by name or ticker symbol: FLGT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Fulgent Genetics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$46.05, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Fulgent Genetics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Fulgent Genetics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Fulgent Genetics's share price?

Since the stock market crash in March caused by coronavirus, Fulgent Genetics's share price has had significant positive movement.

Its last market close was USD$46.05, which is 58.74% up on its pre-crash value of USD$19 and 587.31% up on the lowest point reached during the March crash when the shares fell as low as USD$6.7.

If you had bought USD$1,000 worth of Fulgent Genetics shares at the start of February 2020, those shares would have been worth USD$678.04 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$3,480.92.

Fulgent Genetics share price

Use our graph to track the performance of FLGT stocks over time.

Fulgent Genetics shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$46.05
52-week range	USD$6.7 - USD$52.47
50-day moving average	USD$36.5331
200-day moving average	USD$25.2713
Wall St. target price	USD$56.25
PE ratio	284.3846
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.124

Buy Fulgent Genetics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Fulgent Genetics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Fulgent Genetics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Fulgent Genetics price performance over time

Historical closes compared with the close of $46.05 from 2020-11-16

1 week (2020-11-18)	6.06%
1 month (2020-10-23)	28.45%
3 months (2020-08-25)	0.26%
6 months (2020-05-22)	203.76%

1 year (2019-11-25)	287.63%
2 years (2018-11-23)	1,357.28%
3 years (2017-11-24)	1,246.49%
5 years (2015-11-22)	N/A

Is Fulgent Genetics under- or over-valued?

Valuing Fulgent Genetics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Fulgent Genetics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Fulgent Genetics's P/E ratio

Fulgent Genetics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 284x. In other words, Fulgent Genetics shares trade at around 284x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Fulgent Genetics's PEG ratio

Fulgent Genetics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Fulgent Genetics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Fulgent Genetics's EBITDA

Fulgent Genetics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$4 million.

The EBITDA is a measure of a Fulgent Genetics's overall financial performance and is widely used to measure a its profitability.

Fulgent Genetics financials

Revenue TTM	USD$43.8 million
Operating margin TTM	4.17%
Gross profit TTM	USD$18.4 million
Return on assets TTM	1.5%
Return on equity TTM	3.66%
Profit margin	5.79%
Book value	$3.991
Market capitalisation	USD$824.9 million

TTM: trailing 12 months

Shorting Fulgent Genetics shares

There are currently 1.9 million Fulgent Genetics shares held short by investors – that's known as Fulgent Genetics's "short interest". This figure is 24.2% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Fulgent Genetics shares can be evaluated.

Fulgent Genetics's "short interest ratio" (SIR)

Fulgent Genetics's "short interest ratio" (SIR) is the quantity of Fulgent Genetics shares currently shorted divided by the average quantity of Fulgent Genetics shares traded daily (recently around 1.3 million). Fulgent Genetics's SIR currently stands at 1.49. In other words for every 100,000 Fulgent Genetics shares traded daily on the market, roughly 1490 shares are currently held short.

However Fulgent Genetics's short interest can also be evaluated against the total number of Fulgent Genetics shares, or, against the total number of tradable Fulgent Genetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fulgent Genetics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Fulgent Genetics shares in existence, roughly 90 shares are currently held short) or 0.1533% of the tradable shares (for every 100,000 tradable Fulgent Genetics shares, roughly 153 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Fulgent Genetics.

Find out more about how you can short Fulgent Genetics stock.

Fulgent Genetics share dividends

We're not expecting Fulgent Genetics to pay a dividend over the next 12 months.

Fulgent Genetics share price volatility

Over the last 12 months, Fulgent Genetics's shares have ranged in value from as little as $6.7 up to $52.47. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fulgent Genetics's is 1.7004. This would suggest that Fulgent Genetics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Fulgent Genetics overview

Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Frequently asked questions

• What percentage of Fulgent Genetics is owned by insiders or institutions?

  Currently 58.151% of Fulgent Genetics shares are held by insiders and 58.885% by institutions.

• How many people work for Fulgent Genetics?

  Latest data suggests 139 work at Fulgent Genetics.

• When does the fiscal year end for Fulgent Genetics?

  Fulgent Genetics's fiscal year ends in December.

• Where is Fulgent Genetics based?

  Fulgent Genetics's address is: 4978 Santa Anita Avenue, Temple City, CA, United States, 91780

• What is Fulgent Genetics's ISIN number?

  Fulgent Genetics's international securities identification number is: US3596641098

• What is Fulgent Genetics's CUSIP number?

  Fulgent Genetics's Committee on Uniform Securities Identification Procedures number is: 359664109